11:59 AM EST - Aeterna Zentaris Inc : announced that its Japanese partner, Yakult Honsha, has initiated a Phase 1/2 trial in Japan to assess the safety and efficacy of the Company's PI3K/Akt inhibitor, perifosine, in combination with chemotherapeutic agent, capecitabine, in patients with refractory advanced colorectal cancer. The initiation of this trial will trigger a milestone payment of an undisclosed amount from Yakult to Aeterna Zentaris under the partnership agreement signed with Yakult in March 2011 for perifosine in Japan. Aeterna Zentaris Inc.
shares T.AEZ are trading up $0.04 at $1.60.
